XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
OTHER (INCOME) EXPENSE, NET
 9 Months Ended
Sep. 30, 2017
Other Income and Expenses [Abstract]  
OTHER (INCOME) EXPENSE, NET
OTHER (INCOME) EXPENSE, NET
Other (income) expense, net for the three and nine months ended September 30, 2017 and 2016 were as follows:


Three Months Ended
September 30,

Nine Months Ended
September 30,
(in millions)

2017

2016

2017

2016
Gain on the iNova Sale (Note 4)
 
$
(306
)
 
$
—

 
$
(306
)
 
$
—

Gain on the Skincare Sale (Note 4)

3


—


(316
)

—

Gain on the Dendreon Sale (Note 4)

(25
)

—


(98
)

—

Net loss (gain) on other sales of assets

—


—


25


(9
)
Deconsolidation of Philidor

—


—


—


19

Litigation and other matters

3


1


112


(32
)
Other, net

—


—


(1
)

2

 

$
(325
)

$
1


$
(584
)

$
(20
)

During the three months ended September 30, 2017, the initially reported Gain on the Dendreon Sale was increased by $25 million to reflect working capital adjustments to the initial sales price during the three months ended September 30, 2017. See Note 4, "DIVESTITURES" for details related to the Gain on the Dendreon Sale.
Litigation and other matters includes amounts provided for certain matters discussed in Note 18, "LEGAL PROCEEDINGS". During the nine months ended September 30, 2016, included in Litigation and other matters is a favorable adjustment of $39 million for the settlement related to the investigation into Salix's pre-acquisition sales and promotional practices for the Xifaxan®, Relistor® and Apriso® products during the three months ended June 30, 2016.